1. Home
  2. ALT vs UPXI Comparison

ALT vs UPXI Comparison

Compare ALT & UPXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • UPXI
  • Stock Information
  • Founded
  • ALT 1997
  • UPXI 2018
  • Country
  • ALT United States
  • UPXI United States
  • Employees
  • ALT N/A
  • UPXI N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • UPXI Medicinal Chemicals and Botanical Products
  • Sector
  • ALT Health Care
  • UPXI Health Care
  • Exchange
  • ALT Nasdaq
  • UPXI Nasdaq
  • Market Cap
  • ALT 292.0M
  • UPXI 481.8M
  • IPO Year
  • ALT N/A
  • UPXI 2021
  • Fundamental
  • Price
  • ALT $3.83
  • UPXI $7.23
  • Analyst Decision
  • ALT Strong Buy
  • UPXI
  • Analyst Count
  • ALT 6
  • UPXI 0
  • Target Price
  • ALT $17.40
  • UPXI N/A
  • AVG Volume (30 Days)
  • ALT 3.0M
  • UPXI 8.1M
  • Earning Date
  • ALT 08-12-2025
  • UPXI 05-16-2025
  • Dividend Yield
  • ALT N/A
  • UPXI N/A
  • EPS Growth
  • ALT N/A
  • UPXI N/A
  • EPS
  • ALT N/A
  • UPXI N/A
  • Revenue
  • ALT $20,000.00
  • UPXI $16,562,327.00
  • Revenue This Year
  • ALT N/A
  • UPXI $299.03
  • Revenue Next Year
  • ALT $761,880.20
  • UPXI N/A
  • P/E Ratio
  • ALT N/A
  • UPXI N/A
  • Revenue Growth
  • ALT N/A
  • UPXI 1378.83
  • 52 Week Low
  • ALT $2.90
  • UPXI $1.90
  • 52 Week High
  • ALT $11.16
  • UPXI $22.57
  • Technical
  • Relative Strength Index (RSI)
  • ALT 51.79
  • UPXI 51.85
  • Support Level
  • ALT $3.35
  • UPXI $6.16
  • Resistance Level
  • ALT $3.66
  • UPXI $9.12
  • Average True Range (ATR)
  • ALT 0.19
  • UPXI 0.97
  • MACD
  • ALT 0.07
  • UPXI 0.10
  • Stochastic Oscillator
  • ALT 86.18
  • UPXI 47.86

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About UPXI Upexi Inc.

Upexi Inc specializes in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space via a Solana treasury strategy.

Share on Social Networks: